MNPR - Monopar Therapeutics Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
7,592
7,592
6,493
4,065
1,969
Selling general and administrative
2,945
2,945
2,634
2,444
2,355
Total operating expenses
10,537
10,537
9,127
6,509
4,324
Operating income or loss
-10,537
-10,537
-9,127
-6,509
-4,324
Total other income/expenses net
-
-
-
122.4
-
Income before tax
-10,516
-10,516
-9,103
-6,305
-4,225
Income from continuing operations
-10,516
-10,516
-9,103
-6,305
-4,225
Net income
-10,516
-10,516
-9,103
-6,305
-4,225
Net income available to common shareholders
-10,516
-10,516
-9,103
-6,305
-4,225
Basic EPS
-
-0.83
-0.73
-0.58
-0.45
Diluted EPS
-
-0.83
-0.73
-0.58
-0.45
Basic average shares
-
12,718
12,471
10,958
9,321
Diluted average shares
-
12,718
12,471
10,958
9,321
EBITDA
-
-10,537
-9,127
-6,509
-4,324